Latin America Biguanide Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Latin America Biguanide Market is Segmented Into Geography. The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

Latin America Biguanide Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Latin America Biguanide Market Size

View Global Report
Latin America Biguanide Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
Market Size (2025) USD 397.49 Million
Market Size (2030) USD 456.34 Million
CAGR (2025 - 2030) 2.80 %

Major Players

Latin America Biguanide Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Latin America Biguanide Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Latin America Biguanide Market Analysis

The Latin America Biguanide Market size is estimated at USD 397.49 million in 2025, and is expected to reach USD 456.34 million by 2030, at a CAGR of 2.8% during the forecast period (2025-2030).

Latin America is experiencing a significant surge in the prevalence of diabetes, a chronic condition that affects millions across the region. This rise in diabetes incidence has led to an increased demand for medications to manage the disease, with biguanides emerging as a cornerstone of diabetes treatment. As a result, the biguanide market in Latin America is witnessing robust growth, driven by the escalating diabetes population and the need for effective therapeutic options. 

Biguanides, such as metformin, play a crucial role in the management of type 2 diabetes, the most common form of the disease in Latin America. These medications work by decreasing glucose production in the liver and improving insulin sensitivity in the body, thereby helping to control blood sugar levels. Given their effectiveness, safety profile, and affordability, biguanides have become the first-line therapy for many individuals with type 2 diabetes, particularly those in resource-limited settings.

One of the primary drivers behind the increasing demand for biguanides in Latin America is the region's changing demographic landscape. Urbanization, sedentary lifestyles, and unhealthy dietary habits have contributed to a rise in obesity rates, a key risk factor for type 2 diabetes. Additionally, an aging population and genetic predispositions further exacerbate the diabetes burden in many Latin American countries. As a result, healthcare systems are grappling with the challenge of providing adequate care and treatment for the growing number of individuals diagnosed with diabetes.

Furthermore, the economic burden associated with diabetes is substantial, both for individuals and healthcare systems alike. The costs of managing diabetes-related complications, such as cardiovascular disease, neuropathy, and nephropathy, can be considerable. Therefore, there is a growing emphasis on preventive measures and early intervention strategies, including the use of pharmacotherapy like biguanides to effectively manage the disease and mitigate its long-term complications.

 

Latin America Biguanide Industry Overview

The Latin American biguanide market is fragmented, with manufacturers like Takeda, Merck, Sanofi, GlaxoSmithKline, Bristol-Myers Squibb, Boehringer Ingelheim Pharmaceuticals, etc. having a global market presence, and the market is highly competitive due to generic drug manufacturers' presence.

Latin America Biguanide Market Leaders

  1. Bristol-Myers Squibb

  2. Boehringer Ingelheim

  3. Merck and Co.

  4. Sanofi Aventis

  5. Glenmark Pharmaceuticals

  6. *Disclaimer: Major Players sorted in no particular order
Latin America Biguanide Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Latin America Biguanide Market News

  • February 2023: Zydus Lifesciences Limited, received tentative approval from the FDA for Invokamet tablets (canagliflozin and metformin hydrochloride combination). Canagliflozin and metformin combination products are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing metformin or canagliflozin or in patients already being treated with both canagliflozin and metformin.
  • July 2022: Zydus Lifesciences announced that it received final approval from the FDA to market Empagliflozin and Metformin Hydrochloride tablets in multiple strengths. Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. They are also used to lower the risk of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.

Latin America Biguanide Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Biguanide
  • 5.2 Geography
    • 5.2.1 Mexico
    • 5.2.2 Brazil
    • 5.2.3 Rest of Latin America

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Merck
    • 7.1.2 Takeda
    • 7.1.3 GlaxoSmithKline
    • 7.1.4 Sanofi
    • 7.1.5 Boehringer Ingelheim
    • 7.1.6 Glenmark
    • 7.1.7 Bristol-Myers Squibb
  • *List Not Exhaustive

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
*The report covers a segment-wise breakdown (Value and Volume) for all the countries covered under Table of Contents **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Latin America Biguanide Industry Segmentation

Biguanides are a class of diabetes medications that are used for people with type-2 diabetes. The Latin American biguanide market is segmented by geography. The report offers the value (in USD) and volume (in units) for the above segments. Further, the report will cover a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.

Geography Mexico
Brazil
Rest of Latin America
Need A Different Region or Segment?
Customize Now

Latin America Biguanide Market Research FAQs

How big is the Latin America Biguanide Market?

The Latin America Biguanide Market size is expected to reach USD 397.49 million in 2025 and grow at a CAGR of 2.80% to reach USD 456.34 million by 2030.

What is the current Latin America Biguanide Market size?

In 2025, the Latin America Biguanide Market size is expected to reach USD 397.49 million.

Who are the key players in Latin America Biguanide Market?

Bristol-Myers Squibb, Boehringer Ingelheim, Merck and Co., Sanofi Aventis and Glenmark Pharmaceuticals are the major companies operating in the Latin America Biguanide Market.

What years does this Latin America Biguanide Market cover, and what was the market size in 2024?

In 2024, the Latin America Biguanide Market size was estimated at USD 386.36 million. The report covers the Latin America Biguanide Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Latin America Biguanide Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Latin America Biguanide Industry Report

Statistics for the 2025 Latin America Biguanide market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Latin America Biguanide analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Latin America Biguanide Market Report Snapshots